Skip to main content
Journal cover image

Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF.

Publication ,  Conference
Nouhravesh, N; Gunn, AH; Cyr, D; Hernandez, AF; Morrow, DA; Velazquez, EJ; Ward, JH; Sarwat, S; Sharma, K; Williamson, KM; Starling, RC ...
Published in: Eur J Heart Fail
January 10, 2025

AIMS: Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed. METHODS AND RESULTS: This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status. The primary endpoint was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8. Secondary analyses included a win-ratio analysis of the hierarchical outcome of (i) cardiovascular death; (ii) HF hospitalizations; (iii) urgent HF visits; and (iv) time-averaged proportional change in NT-proBNP from baseline to weeks 4 and 8, in addition to safety outcomes. Among 466 patients, 107 (23%) were ACEi/ARB naïve at the time of randomization. NT-proBNP favoured Sac/Val irrespective of ACEi/ARB status (naïve: 0.76, 95% confidence interval [CI] 0.51-1.13; users: 0.88, 95% CI 0.74-1.05; pinteraction = 0.52). The win ratio of the hierarchical outcome was 1.13 (95% CI 0.86-1.49) for ACEi/ARB users and 1.38 (95% CI 0.81-2.37) for ACEi/ARB naïve (pinteraction = 0.51). Safety endpoints showed non-significant interactions by ACEi/ARB status, with odds ratio of 1.79 (95% CI 0.68-4.72) and 0.71 (95% CI 0.29-1.78) for symptomatic hypotension and worsening renal function, respectively for ACEi/ARB naïve. CONCLUSION: In HF with EF >40% stabilized after worsening HF, safety and efficacy were similar irrespective of ACEi/ARB status at baseline, supporting early initiation irrespective of prior ACEi/ARB use.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

January 10, 2025

Location

England

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nouhravesh, N., Gunn, A. H., Cyr, D., Hernandez, A. F., Morrow, D. A., Velazquez, E. J., … Mentz, R. J. (2025). Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF. In Eur J Heart Fail. England. https://doi.org/10.1002/ejhf.3579
Nouhravesh, Nina, Alexander H. Gunn, Derek Cyr, Adrian F. Hernandez, David A. Morrow, Eric J. Velazquez, Jonathan H. Ward, et al. “Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF.” In Eur J Heart Fail, 2025. https://doi.org/10.1002/ejhf.3579.
Nouhravesh N, Gunn AH, Cyr D, Hernandez AF, Morrow DA, Velazquez EJ, et al. Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF. In: Eur J Heart Fail. 2025.
Nouhravesh N, Gunn AH, Cyr D, Hernandez AF, Morrow DA, Velazquez EJ, Ward JH, Sarwat S, Sharma K, Williamson KM, Starling RC, Lepage S, Zieroth S, Solomon SD, Mentz RJ. Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF. Eur J Heart Fail. 2025.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

January 10, 2025

Location

England

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology